Intellia Therapeutics, Inc. (NTLA)

NGM – Real Time Price. Currency in USD

16.68

+0.65 (4.05%)

At close: Jun 26, 2026, 4:00 PM EDT

16.61

-0.07 (-0.42%)

After-hours: Jun 26, 2026, 7:58 PM EDT

16.06.2026

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.

16.06.2026

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

15.06.2026

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock is trading higher on Monday on additional positive findings from its global Phase 3 HAELO trial evaluating lonvo-z, its investigational CRISPR-based treatment for hereditary angioedema (HAE).

13.06.2026

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul, Türkiye. Results from the trial were simultaneously published in the New England Journal of Medicine. The presentation and publication can be accessed from the Scientific Publications and Presentations section of intelliatx.com.

10.06.2026

Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?

Intellia Therapeutics (NTLA) reported earnings 30 days ago. What's next for the stock?

05.06.2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on June 1, 2026, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

03.06.2026

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't

Buffett, as CEO of Berkshire Hathaway, delivered six decades of market-beating returns. Abel took over the CEO role in January and aims to follow the path traced by the investing giant.

Videos

No Data

There is no data to display

Press releases

13.06.2026

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

05.06.2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11.05.2026

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the first quarter ended March 31, 2026.

01.05.2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on May 1, 2026, it awarded inducement grants to 43 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

Intellia Therapeutics, Inc. (NTLA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Intellia Therapeutics, Inc. (NTLA)

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't

Videos

No Data

Press releases

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't

Videos

No Data

Press releases

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Intellia Therapeutics, Inc. (NTLA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Intellia Therapeutics, Inc. (NTLA)

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't

Videos

No Data

Press releases

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't

Videos

No Data

Press releases

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)